查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994095

噬菌體市場：2026-2032年全球市場預測（依噬菌體類型、給藥途徑、製劑、生產流程、應用及最終用戶分類）

Bacteriophage Market by Phage Type, Administration Route, Formulation, Production Process, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年噬菌體市場價值為 5,283 萬美元，預計到 2026 年將成長至 5,859 萬美元，複合年成長率為 5.45%，到 2032 年將達到 7,661 萬美元。

主要市場統計數據
基準年 2025 5283萬美元
預計年份：2026年 5859萬美元
預測年份：2032年 7661萬美元
複合年成長率 (%) 5.45%

對噬菌體技術和市場現實進行策略概述，探討影響研發、監管參與和跨部門部署管道的因素。

噬菌體科學已從微生物學的一個細分領域發展成為一個跨學科平台，涵蓋治療、診斷、農業、食品安全和動物健康等領域。基因組學、製劑科學和可擴展生產平台的最新進展提高了基於噬菌體的解決方案的技術可行性。同時，快速病原體檢測和噬菌體分型技術的進步也增強了標靶干預的提案。因此，包括研究機構、醫院、食品加工商和農場在內的相關人員正在重新評估噬菌體在更廣泛的抗菌作用和生物安全策略中的作用。

識別噬菌體科學、商業化、臨床接受度和生產製造方面的變革性變化，這些變化正在推動新的策略轉折點。

近年來，一系列變革性因素重新定義了噬菌體從實驗室概念轉化為實際應用的過程。精準基因組編輯技術的進步使得開發具有客製化宿主範圍和有效載荷的重組噬菌體成為可能，從而提高了噬菌體的療效和商業性價值。同時，快速診斷技術和生物感測器整合技術的進步，透過縮短標靶時間和實現適應性治療策略，增強了噬菌體產品的臨床和農場效用。這些技術的融合正推動著噬菌體產品架構從單一模式轉向更模組化、標靶化的方向。

評估 2025 年美國關稅對噬菌體供應鏈、成本結構、國際貿易流動和國內生產的累積影響。

2025年美國的關稅政策可能對噬菌體產品的研發和分銷的經濟效益和物流產生重大影響。進口實驗室試劑、專用一次性系統和分析儀器的關稅壓力可能會增加研究機構和契約製造製造商的上游製程成本。因此，預計籌資策略將轉向具有國內生產能力的供應商並實現貨源多元化，這就要求企業將關稅風險納入其採購計劃和價格談判中。

關鍵細分洞察揭示了應用、最終用戶、噬菌體分類、給藥途徑、配方和製造方法如何影響商業化。

細分市場分析闡明了不同應用領域、最終用戶、噬菌體類型、給藥途徑、製劑選擇和生產流程在技術要求、應用趨勢和經營模式的差異。在應用領域中，噬菌體的應用案例包括農業、動物健康、診斷、食品安全和人類治療。農業領域著重於植物保護、種子處理和土壤改良，這些領域對穩定性、給藥方法和監管證據的要求各不相同。動物健康領域又細分為水產養殖、伴侶動物和畜牧業，這些領域在劑型、給藥途徑和停藥期方面都有顯著差異。診斷領域包括生物感測器、病原體檢測和噬菌體分型，這些領域都強調靈敏度、速度以及與實驗室工作流程的整合。食品安全應用領域著重於乳製品、肉類和農產品的分銷管道，需要在加工條件下進行嚴格的驗證。人類治療領域涵蓋皮膚病、消化器官系統、感染疾病和呼吸系統疾病，而感染疾病領域則根據細菌感染疾病和生物膜相關疾病帶來的具體挑戰進一步細分。

區域洞察重點分析美洲、歐洲、中東和非洲以及亞太地區噬菌體技術市場的不同促進因素和障礙。

區域趨勢對噬菌體解決方案在各市場的開發、監管和應用方式有顯著影響。在美洲，監管機構和採購管道強調用於臨床准入的可操作管道，私營部門對治療和農業應用領域都有大量投資。因此，在有報銷和採購獎勵的地區，噬菌體解決方案的推廣應用迅速，但這同時也需要應對複雜的聯邦和州級生技藥品監管。歐洲、中東和非洲的監管環境則不盡相同。歐洲部分地區擁有完善的框架，以促進臨床試驗和有條件核准的協調，而該地區不同司法管轄區的監管成熟度則存在差異。這些差異為區域中心的建立創造了機遇，這些中心可以支持跨多個司法管轄區的研究和供應鏈。

深入了解競爭對手和合作夥伴，並專注於塑造噬菌體領域的實力、規模、智慧財產權趨勢和策略夥伴關係。

在公司層面，趨勢表明，能力累積、策略夥伴關係和智慧財產權組合正在決定企業的競爭地位。擁有強大的研發能力、生產規模和監管合規經驗的公司最有利於透過臨床和商業管道推廣產品。同時，規模小規模、專注於特定領域的生物技術公司和大學衍生企業正在噬菌體工程、遞送技術和細分應用領域推動重大創新，從而形成一個從上游發現到下游規模化生產的充滿活力的生態系統。

為行業領導者提供切實可行的建議，以加速產品開發、降低商業化風險、最佳化生產製造以及協調監管和市場策略。

產業領導者應優先考慮整合技術開發、監管策略、生產準備和終端用戶參與的綜合方法。首先，應投資進行嚴格的特性分析和穩定性測試，以滿足監管申報和採購競標中預期的證據要件。這有助於減少後期階段的不確定性，並促進與監管機構的建設性對話。其次，應制定生產藍圖，既包含透過契約製造(CMO) 實現的短期方案，也包含用於建構本地生產能力的中期計劃。這種雙管齊下的方法有助於應對關稅風險和供應中斷。

本書詳細介紹了用於支持研究結果的可靠調查方法，包括一手和二手調查、專家檢驗、數據三角測量和情境分析。

本分析所依據的研究採用了一種混合方法，結合了與關鍵相關人員的對話、詳盡的二手資料研究和專家檢驗。一手資料研究包括對研究機構、契約製造、臨床網路、食品加工企業和監管事務部門的領導者進行結構化訪談，以了解實際的限制因素、採購因素和證據要求。這些訪談有助於提出假設，並幫助確定最具影響力的技術和市場動態的優先順序。

簡明扼要的結論整合了有關技術進步、監管趨勢、供應鏈韌性和相關人員。

總之，噬菌體技術正處於一個轉折點，科學進步、製造創新、監管調整和市場需求在此交匯融合，為治療、診斷、農業、食品安全和動物健康領域創造了切實的機會。工程技術的成熟，以及製劑和檢測技術的進步，使得更精準、更實用的解決方案成為可能；同時，不斷完善的法規結構也在逐步適應噬菌體產品的獨特特性。供應鏈設計和關稅環境正在影響生產基地選擇和採購方面的戰術性決策，凸顯了韌性和多元化的戰略重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：噬菌體市場：依噬菌體類型分類

  • 改良噬菌體
  • 溶菌噬菌體
  • 溫和噬菌體

第9章：噬菌體市場：依給藥途徑分類

  • 吸入
  • 靜脈
  • 口服
  • 外用

第10章：噬菌體市場：依製劑類型分類

  • 膠囊製劑
  • 液體
  • 冷凍乾燥製劑

第11章：噬菌體市場：依生產製程分類

  • 發酵
  • 合成製造

第12章：噬菌體市場：依應用領域分類

  • 農業
    • 植物保護
    • 種子處理
    • 土壤改良
  • 動物健康
    • 水產養殖
    • 伴侶動物
    • 家畜
  • 診斷
    • 生物修復
    • 病原體檢測
    • 噬菌體分型
  • 食品安全
    • 乳製品
    • 肉類
    • 農產品
  • 人類治療
    • 皮膚科
    • 消化器官系統
    • 感染疾病
      • 細菌感染疾病
      • 生物膜相關
    • 呼吸系統

第13章：噬菌體市場：依最終用戶分類

  • 畜牧場
  • 食品加工公司
  • 醫院
  • 研究機構

第14章 噬菌體市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：噬菌體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 噬菌體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國噬菌體市場

第18章：中國的噬菌體市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptive Phage Therapeutics, Inc.
  • APS Biocontrol Ltd.
  • Armata Pharmaceuticals, Inc.
  • BiomX Ltd.
  • Eliava Biopreparations Ltd.
  • Eligo Bioscience SA
  • EnBIoTix, Inc.
  • Fixed-Phage Limited
  • InnoPhage, Ltd.
  • iNtODEWORLD, Inc.
  • Intralytix, Inc.
  • Locus Biosciences, Inc.
  • Micreos BV
  • NextbIoTics, Inc.
  • Phagelux, Inc.
  • PhagePro, Inc.
  • Phagomed Biopharma GmbH
  • Pherecydes Pharma
  • Proteon Pharmaceuticals SA
  • TechnoPhage SA
Product Code: MRR-1A1A064C03A9

The Bacteriophage Market was valued at USD 52.83 million in 2025 and is projected to grow to USD 58.59 million in 2026, with a CAGR of 5.45%, reaching USD 76.61 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 52.83 million
Estimated Year [2026] USD 58.59 million
Forecast Year [2032] USD 76.61 million
CAGR (%) 5.45%

Strategic introduction to bacteriophage technologies and market realities shaping research, development, regulatory dialogue, and cross-sector adoption pathways

Bacteriophage science has evolved from a niche microbiological discipline into a multidisciplinary platform that intersects therapeutics, diagnostics, agriculture, food safety, and animal health. Recent advances in genomic engineering, formulation science, and scalable production platforms have increased the technical feasibility of phage-based solutions, while parallel improvements in rapid pathogen detection and phage typing have strengthened the value proposition for targeted interventions. Consequently, stakeholders across research institutions, hospitals, food processors, and farms are reassessing where bacteriophages fit within broader antimicrobial stewardship and biosecurity strategies.

At the same time, regulatory frameworks are gradually adapting to accommodate novel biologics that do not conform to traditional small-molecule paradigms. This transition imposes new evidentiary expectations while also opening pathways for conditional and compassionate use in selected settings. In addition, the growth of contract manufacturing and modular fermentation capabilities is lowering the barrier to scale for specialized producers, even as supply chain complexity persists for critical reagents and equipment. Taken together, these structural shifts are reshaping investment priorities, partnership models, and product roadmaps for companies operating in the bacteriophage ecosystem.

This introduction sets the stage for deeper analysis of the technological enablers, market-facing requirements, and cross-sector adoption dynamics that inform strategic decisions today and in the coming planning horizons.

Identifying transformative shifts in bacteriophage science, commercialization, clinical acceptance, and manufacturing that are driving new strategic inflection points

In recent years a cluster of transformative forces has redefined how bacteriophages move from laboratory concepts to deployable solutions. Advances in precision genome editing have enabled engineered phages with tailored host ranges and payloads, increasing both efficacy and commercial attractiveness. Simultaneously, improvements in rapid diagnostics and biosensor integration have strengthened the clinical and on-farm utility of phage products by reducing time-to-target and enabling adaptive treatment strategies. These technological convergences are catalyzing a shift from one-size-fits-all approaches to more modular, targeted product architectures.

Operationally, there is an accelerating emphasis on manufacturing robustness and formulation stability, with encapsulation and lyophilization techniques extending shelf life and enabling broader routes of administration. This capacity expansion is occurring alongside new regulatory dialogues that emphasize safety, traceability, and post-market surveillance, thereby influencing trial design and go-to-market sequencing. Moreover, cross-sector collaborations-linking academic labs, contract manufacturers, and clinical networks-are creating hybrid commercialization models that spread technical risk while concentrating expertise where it matters most.

As a result, incumbents and new entrants must reassess their value propositions, invest selectively in platform capabilities, and build flexible supply chain arrangements to capture emergent opportunities across therapeutics, diagnostics, agriculture, and food safety.

Assessing the cumulative impact of United States tariffs in 2025 on bacteriophage supply chains, cost structures, international trade flows, and domestic production

Tariff policy in the United States during 2025 has the potential to materially influence the economics and logistics of bacteriophage product development and distribution. Tariff-induced cost pressures on imported laboratory reagents, specialized single-use systems, and analytical instrumentation can increase upstream expenses for both research organizations and contract manufacturers. Consequently, procurement strategies are likely to pivot toward suppliers with domestic capacity or diversified sourcing arrangements, and companies will need to incorporate tariff risk into procurement planning and price negotiations.

Beyond direct cost impacts, tariffs can alter cross-border collaboration patterns. When import duties raise the cost of key inputs or finished goods, organizations may accelerate domestic partnerships or invest in local manufacturing to preserve margins and maintain supply continuity. This trend is particularly relevant for high-value, temperature-sensitive formulations where logistics complexity already commands significant attention. Conversely, tariffs can reduce the competitiveness of exported phage-based products, prompting exporters to seek tariff mitigation through product localization, co-manufacturing agreements, or tariff classification strategies that favor lower-duty pathways.

Regulatory and procurement stakeholders should also consider the secondary effects of tariff regimes on innovation pipelines. Increased import costs may incentivize manufacturers to optimize production processes, reduce reliance on single-sourced components, and pursue synthetic or fermentation-based workflows that are less exposed to cross-border tariff volatility. In short, tariffs in 2025 are not simply a near-term cost issue; they are a catalyst for supply chain redesign, strategic localization, and operational resilience that will shape the bacteriophage landscape beyond an immediate fiscal cycle.

Key segmentation insights revealing how applications, end users, phage typologies, administration routes, formulations, and production methods influence commercialization

Segmentation analysis clarifies where technical requirements, adoption dynamics, and commercial models diverge across applications, end users, phage types, administration routes, formulation choices, and production processes. In the application domain, bacteriophage use cases span Agriculture, Animal Health, Diagnostics, Food Safety, and Human Therapeutics. Within Agriculture the emphasis is split among plant protection, seed treatment, and soil amendment, each demanding different stability, delivery, and regulatory evidence profiles. Animal Health subdivides into aquaculture, companion animals, and livestock, where dosage forms, route of administration, and withdrawal considerations vary considerably. Diagnostics includes biosensors, pathogen detection, and phage typing, all of which place a premium on sensitivity, speed, and integration with laboratory workflows. Food Safety applications concentrate on dairy, meat, and produce pathways, requiring robust validation under processing conditions. Human Therapeutics covers dermatology, gastrointestinal, infectious diseases, and respiratory indications, with infectious diseases further differentiated by the specific challenges posed by bacterial infections and biofilm-associated conditions.

Complementing application-focused segmentation, end users encompass animal farms, food processing companies, hospitals, and research institutions, each with distinct procurement cycles, risk tolerances, and operational constraints. Phage typologies-engineered phages, lytic phages, and temperate phages-carry divergent regulatory and IP considerations that affect development timelines and partner selection. Administration routes including inhalation, intravenous, oral, and topical determine formulation strategy and cold chain needs, while formulation formats such as encapsulated, liquid, and lyophilized presentations influence shelf life and logistics. Finally, production choices between fermentation and synthetic manufacturing govern scalability, cost structure, and upstream supply dependencies. Together these segmentation layers create a complex matrix of product design and go-to-market options, and they underscore the importance of aligning technical capabilities with the specific requirements of target applications and end users.

Regional insights highlighting differentiated drivers and barriers across the Americas, Europe Middle East and Africa, and Asia Pacific markets for bacteriophage technologies

Regional dynamics materially affect how bacteriophage solutions are developed, regulated, and adopted across different markets. In the Americas regulatory agencies and procurement channels emphasize pragmatic pathways for clinical access, and there is strong private-sector investment in both therapeutic and agricultural applications. This results in rapid adoption in contexts where reimbursement or procurement incentives exist, but also requires navigation of complex federal and state-level oversight for live biologics. In Europe, Middle East & Africa, the regulatory landscape is heterogeneous: parts of Europe have advanced frameworks that facilitate clinical trial harmonization and conditional approvals, while other jurisdictions within the broader region present varying levels of regulatory maturity. These differences create opportunities for regional hubs that can support multi-jurisdictional studies and supply chains.

In Asia-Pacific, the combination of large agricultural sectors, high-density aquaculture operations, and emerging biotech innovation clusters is driving a distinct set of use cases and commercialization approaches. Regulatory modernization in several Asia-Pacific markets is accelerating local clinical workstreams and domestic manufacturing capacity, which in turn supports faster on-the-ground deployment. Across all regions there is a consistent premium on building local evidence of efficacy and safety, addressing logistics and cold chain challenges, and establishing trusted distribution channels. Moreover, regional procurement policies and tariff environments influence where organizations choose to site production and how they structure cross-border partnerships.

Competitive and collaborative company insights emphasizing capabilities, scale, intellectual property trends, and strategic partnerships shaping the bacteriophage landscape

Company-level dynamics reveal a landscape where capability clusters, strategic partnerships, and IP portfolios determine competitive positioning. Firms that combine robust R&D operations with manufacturing scale and regulatory experience are best positioned to move products into clinical and commercial channels. At the same time, smaller specialized biotechs and academic spinouts contribute critical innovation around phage engineering, delivery technologies, and niche applications, creating a vibrant ecosystem of upstream discovery and downstream scale-up.

Partnership models are particularly important: contract development and manufacturing organizations, diagnostic integrators, and agriculture-focused distributors provide the operational muscle that enables innovators to reach end users. Intellectual property strategies matter not only for protecting engineered constructs but also for securing freedom to operate around manufacturing processes and formulation technologies. Additionally, companies that proactively engage with regulatory agencies and invest in transparent safety and surveillance programs tend to reduce commercialization timelines and build trust with purchasing decision-makers.

Finally, access to capital and the ability to demonstrate reproducible manufacturing and clinical evidence remain critical gating factors. Investors and partners are increasingly looking for demonstrable translational milestones, credible risk mitigation plans, and the operational readiness to scale production while maintaining stringent quality control.

Actionable recommendations for industry leaders to accelerate development, de-risk commercialization, optimize manufacturing, and align regulatory and market strategies

Industry leaders should prioritize an integrated approach that links technology development with regulatory strategy, manufacturing readiness, and end-user engagement. First, invest in rigorous characterization and stability studies that align with anticipated evidence requirements for regulatory submissions and procurement tenders. This reduces later-stage uncertainty and facilitates constructive dialogue with authorities. Second, design manufacturing roadmaps that include both short-term options through contract manufacturing organizations and medium-term plans for localized capacity; such dual-track approaches help manage tariff exposures and supply interruptions.

Third, pursue targeted partnerships that connect discovery teams with distribution channels in hospitals, food processing, and agricultural sectors. These relationships accelerate adoption by embedding phage solutions into existing operational workflows and by generating real-world performance data. Fourth, adopt a modular product architecture that accommodates different administration routes and formulation formats, thereby increasing addressable use cases while streamlining development effort. Finally, build a transparent post-market surveillance framework to monitor efficacy, resistance patterns, and safety, and use that evidence to refine indications, dosing strategies, and messaging to payers and procurement bodies.

Taken together, these recommendations support de-risked commercialization, scalable manufacturing, and credible engagement with regulators and end users, enabling organizations to convert scientific potential into sustained impact.

Robust research methodology detailing primary and secondary approaches, expert validation, data triangulation, and scenario analysis used to underpin findings

The research underpinning this analysis used a mixed-methods approach combining primary stakeholder engagement with exhaustive secondary review and expert validation. Primary research included structured interviews with leaders in research institutions, contract manufacturing, clinical networks, food processing operations, and regulatory affairs to capture real-world constraints, procurement drivers, and evidence expectations. These interviews informed hypothesis generation and helped prioritize the most consequential technology and market dynamics.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, patent filings, and publicly available technical briefs to map technological trajectories and historical precedent. Data triangulation methods were applied to reconcile differing perspectives, and scenario analysis was used to stress-test assumptions about supply chain shocks, regulatory timelines, and adoption velocity. Expert panels provided iterative validation of key findings and guided the construction of strategic recommendations, while methodological transparency was maintained through documented interview protocols, source logs, and a reproducible analytical framework.

This blended methodology ensures the conclusions are grounded in empirical observation, validated by domain experts, and robust to a range of plausible futures, thereby supporting actionable decision-making for executives and investors.

Concise conclusion synthesizing evidence on technological progress, regulatory momentum, supply chain resilience, and strategic imperatives for stakeholders

In conclusion, bacteriophage technologies are at an inflection point where scientific progress, manufacturing innovation, regulatory adaptation, and market demand converge to create tangible opportunities across therapeutics, diagnostics, agriculture, food safety, and animal health. The maturation of engineering techniques, coupled with advances in formulation and detection technologies, enables more precise and deployable solutions, while evolving regulatory frameworks are gradually accommodating the special characteristics of phage-based products. Supply chain design and tariff environments will influence tactical decisions about production siting and sourcing, underscoring the strategic importance of resilience and diversification.

Companies that succeed will be those that align rigorous technical evidence with pragmatic manufacturing plans, proactive regulatory engagement, and deep end-user partnerships. By adopting modular product architectures, investing in demonstrable safety and surveillance programs, and building flexible supply chains, organizations can move from proof-of-concept to routine deployment. Ultimately, the most consequential progress will stem from integrated approaches that convert scientific capability into operationally reliable, economically viable, and clinically or operationally effective solutions for the stakeholders who depend on them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bacteriophage Market, by Phage Type

  • 8.1. Engineered Phages
  • 8.2. Lytic Phages
  • 8.3. Temperate Phages

9. Bacteriophage Market, by Administration Route

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Bacteriophage Market, by Formulation

  • 10.1. Encapsulated Formulation
  • 10.2. Liquid Formulation
  • 10.3. Lyophilized Formulation

11. Bacteriophage Market, by Production Process

  • 11.1. Fermentation
  • 11.2. Synthetic Manufacturing

12. Bacteriophage Market, by Application

  • 12.1. Agriculture
    • 12.1.1. Plant Protection
    • 12.1.2. Seed Treatment
    • 12.1.3. Soil Amendment
  • 12.2. Animal Health
    • 12.2.1. Aquaculture
    • 12.2.2. Companion Animals
    • 12.2.3. Livestock
  • 12.3. Diagnostics
    • 12.3.1. Biosensors
    • 12.3.2. Pathogen Detection
    • 12.3.3. Phage Typing
  • 12.4. Food Safety
    • 12.4.1. Dairy
    • 12.4.2. Meat
    • 12.4.3. Produce
  • 12.5. Human Therapeutics
    • 12.5.1. Dermatology
    • 12.5.2. Gastrointestinal
    • 12.5.3. Infectious Diseases
      • 12.5.3.1. Bacterial Infections
      • 12.5.3.2. Biofilm Associated
    • 12.5.4. Respiratory

13. Bacteriophage Market, by End User

  • 13.1. Animal Farms
  • 13.2. Food Processing Companies
  • 13.3. Hospitals
  • 13.4. Research Institutions

14. Bacteriophage Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bacteriophage Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bacteriophage Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Bacteriophage Market

18. China Bacteriophage Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Adaptive Phage Therapeutics, Inc.
  • 19.6. APS Biocontrol Ltd.
  • 19.7. Armata Pharmaceuticals, Inc.
  • 19.8. BiomX Ltd.
  • 19.9. Eliava Biopreparations Ltd.
  • 19.10. Eligo Bioscience SA
  • 19.11. EnBiotix, Inc.
  • 19.12. Fixed-Phage Limited
  • 19.13. InnoPhage, Ltd.
  • 19.14. iNtODEWORLD, Inc.
  • 19.15. Intralytix, Inc.
  • 19.16. Locus Biosciences, Inc.
  • 19.17. Micreos BV
  • 19.18. Nextbiotics, Inc.
  • 19.19. Phagelux, Inc.
  • 19.20. PhagePro, Inc.
  • 19.21. Phagomed Biopharma GmbH
  • 19.22. Pherecydes Pharma
  • 19.23. Proteon Pharmaceuticals S.A.
  • 19.24. TechnoPhage SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BACTERIOPHAGE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BACTERIOPHAGE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 258. GCC BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. GCC BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. G7 BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 312. NATO BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 314. NATO BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)